Last reviewed 2026-05-16 · How we verify

TD Vaccines A/S — Portfolio Competitive Intelligence Brief

TD Vaccines A/S pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

• Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. Advaxis, Inc. · 1 shared drug class
2. Agenus Inc. · 1 shared drug class
3. European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class
4. Fundacion Clinic per a la Recerca Biomédica · 1 shared drug class
5. Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 shared drug class
6. Merck KGaA, Darmstadt, Germany · 1 shared drug class
7. National Cancer Institute (NCI) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TD Vaccines A/S:

• TD Vaccines A/S pipeline updates — RSS
• TD Vaccines A/S pipeline updates — Atom
• TD Vaccines A/S pipeline updates — JSON

Cite this brief

Drug Landscape (2026). TD Vaccines A/S — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/td-vaccines-a-s. Accessed 2026-05-16.

Related

• TD Vaccines A/S full company profile
• All CI briefs
• Build a custom feed